Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Inclusion Criteria:

• Documented chronic (at least 6 months) HCV GT 1 infection (with no evidence of mixedgenotypes or genotype that cannot be assigned a type)

• Evidence or no evidence of liver cirrhosis based on one of the following:

• Liver biopsy performed within 24 months of Day 1 (if participant is cirrhotic thenthere is no time restriction on biopsy)

• Fibroscan performed within 12 months of Day 1 of this study

• Fibrosure™ (Fibrotest™) plus aspartate aminotransferase to platelet Ratio Index [APRI]obtained during the screening period)

• Has HCV status that is one of the following:

• Treatment naïve

• Prior interferon or pegylated interferon with or without ribavarin failures (nullresponder, partial responder, or relapser)

• Intolerant to prior interferon or pegylated intereferon with or without ribavarinregimen

• Chronic kidney disease (defined as glomerular filtration rate [eGFR] <=29)non-dialysis dependent or on hemodialysis for at least 3 months, including individualsawaiting kidney transplant and those with failed kidney transplants but no longer onimmunosuppressant therapy)

• Female participant of reproductive potential must agree to remain abstinent or use (orhave their partner use) 2 acceptable methods of contraception from at least 2 weeksprior to Day 1 through 14 days after the last dose of study drugs, or longer ifdictated by local regulations

Exclusion Criteria:

• Evidence of decompensated liver disease

• On peritoneal dialysis for management of kidney disease

• Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

• History of malignancy <=5 years prior to signing informed consent

• Clinical diagnosis of substance abuse

• Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm fromDay 1 through 14 days after the last study dose, or longer if dictated by localregulations

• Organ transplant (including hematopoietic stem cell transplant) other than kidney,cornea, and hair

• Conditions requiring, or likely to require, chronic systemic administration ofcorticosteroids during the course of the trial

• Uncontrolled or poorly controlled hypertension

• Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina) orcardiovascular procedure within 3 months prior to signing informed consent

• New or worsening signs or symptoms of congestive heart failure within 3 months ofsigning informed consent

• Severe active peripheral vascular disease

• Recent (within 3 months prior to signing informed consent) episode or recurrence ofstroke, transient ischemic attack (TIA) or neurological disorder, including but notlimited to seizures

• Evidence or history of chronic hepatitis not caused by HCV